RNF112 and astrocytoma (excluding glioblastoma): In another GSE4271-GPL97 database (n = 77) containing 27.3% malignant grade III astrocytomas and 72.7% grade IV GBM patients, those with low Znf179 expression levels (n = 56) were significantly associated with a poor prognosis and survival rates (p = 0.032) (Fig. 5B).